Human iPSC biobanking for drug discovery sales will expand through 2036, with iPSC lines at 42.4% of the product type category, drug discovery at 30.7% of application demand and pharmaceutical companies at 35.0% of end user sales in 2026. The market is projected to record an 11.2% CAGR between 2026 and 2036.